Teva Pharmaceutical Industries Limited (TEV) — Free Cash Flow Generation Index
Teva Pharmaceutical Industries Limited (TEV) has a Free Cash Flow Generation Index of 0.88x as of December 2025. Free cash flow of €1.02 Billion represents 1% of operating cash flow (€1.16 Billion). Read TEV current and long-term liabilities for a breakdown of total debt and financial obligations.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Teva Pharmaceutical Industries Limited Free Cash Flow Generation Index (2015–2025)
Historical FCF Generation Index trend for Teva Pharmaceutical Industries Limited across 11 annual periods. Explore TEV capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
Annual Free Cash Flow Generation for Teva Pharmaceutical Industries Limited (2015–2025)
Year-by-year Free Cash Flow Generation Index for Teva Pharmaceutical Industries Limited. For the full company profile including market capitalisation, see market value of Teva Pharmaceutical Industries Limited.
| Year | FCG Index | Free Cash Flow (EUR) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.70x | €1.15 Billion | €1.65 Billion | €501.00 Million | ▲ +15.9% |
| 2024 | 0.60x | €749.00 Million | €1.25 Billion | €498.00 Million | ▲ +14.3% |
| 2023 | 0.53x | €608.00 Million | €1.16 Billion | €549.00 Million | ▼ -19.8% |
| 2022 | 0.66x | €1.04 Billion | €1.59 Billion | €548.00 Million | ▲ +121.6% |
| 2021 | 0.30x | €236.00 Million | €798.00 Million | €562.00 Million | ▼ -43.6% |
| 2020 | 0.52x | €638.00 Million | €1.22 Billion | €578.00 Million | ▲ +76.0% |
| 2019 | 0.30x | €223.00 Million | €748.00 Million | €525.00 Million | ▼ -59.4% |
| 2018 | 0.73x | €1.79 Billion | €2.45 Billion | €651.00 Million | ▼ -38.0% |
| 2017 | 1.18x | €2.63 Billion | €2.23 Billion | €874.00 Million | ▼ -3.9% |
| 2016 | 1.23x | €4.79 Billion | €3.89 Billion | €901.00 Million | ▲ +8.1% |
| 2015 | 1.14x | €6.31 Billion | €5.54 Billion | €772.00 Million | — |